ONO-4538 Phase III Study A Multicenter, Double-Blind, Randomized Study in Patients With Unresectable Advanced or Recurrent Gastric Cancer

Trial Profile

ONO-4538 Phase III Study A Multicenter, Double-Blind, Randomized Study in Patients With Unresectable Advanced or Recurrent Gastric Cancer

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Jan 2017

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Gastric cancer
  • Focus Therapeutic Use
  • Sponsors Ono Pharmaceutical
  • Most Recent Events

    • 21 Jan 2017 Results (Data cut-off Aug 13, 2016) presented at the 2017 Gastrointestinal Cancers Symposium
    • 20 Jan 2017 Results presented at the 2017 Gastrointestinal Cancer Symposium (ASCO GI 2017), as per an Ono Pharmaceuticals media release.
    • 20 Jan 2017 Results published in an Ono Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top